Mintreleq Xl (Quetiapine)

Quetiapine works by blocking serotonin 5‑HT2A and dopamine D2 receptors while partially stimulating 5‑HT1A receptors. This combined antagonism and partial agonism modulates neurotransmission involved in psychosis and mood regulation, helping to reduce hallucinations, delusions, and mood swings.

The appropriate dose of Mintreleq Xl is determined individually by a qualified prescriber based on the patient’s diagnosis, response to therapy, and tolerability. Dosing may be adjusted over time, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for quetiapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their physician.

To order Mintreleq Xl, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mintreleq Xl (quetiapine) shares the broad receptor profile typical of atypical antipsychotics but is distinguished by its relatively strong antihistaminic effect, which can cause more sedation and weight gain compared with agents such as aripiprazole or ziprasidone. Choice of therapy depends on individual symptom patterns, side‑effect tolerance and clinician experience.

Store Mintreleq Xl at ambient temperature, preferably below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Mintreleq Xl is taken orally, usually once or twice daily as directed by a prescriber. Tablets should be swallowed whole with water and may be taken with or without food. Patients should not crush, chew, or split the tablets unless specifically instructed.

Serious risks include neuroleptic malignant syndrome, agranulocytosis, severe hypotension, tardive dyskinesia, and emergent suicidal thoughts, especially during early treatment or dose changes. Patients should seek immediate medical attention if they experience high fever, muscle rigidity, unexplained infections, fainting, or worsening mood symptoms.

Mintreleq Xl is contraindicated in individuals with known hypersensitivity to quetiapine or any of its excipients. Caution is advised for patients with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of neuroleptic malignant syndrome. It should not be used in combination with other dopamine‑blocking agents without specialist supervision.